ArticleKidney research and clinical practice2025
High-volume online hemodiafiltration versus high-flux hemodialysis: a short review of recent evidence and a discussion on clinical implementation.
Article in Kidney research and clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Online hemodiafiltration (HDF) has received significant attention as a potentially superior dialysis modality compared to conventional high-flux hemodialysis for patients with end-stage kidney disease. The CONVINCE (CONvective VERSus diffusive dialysis in patients with End-stage kidney disease) trial, subsequent meta-analyses, and observational studies indicate that high-dose HDF (≥23 L convection per session) is associated with improved survival outcomes, particularly through reductions in cardiovascular and possibly also infection-related mortality. Additionally, emerging evidence suggests modest but meaningful benefits in health-related quality of life and symptom control. This comment synthesizes the current literature (2022-2025), highlighting clinical outcomes, patient-centered metrics, feasibility, cost-effectiveness, personalized treatment considerations, and implications for clinical practice. Additionally, practical prescription guidance is provided to assist nephrologists in achieving optimal convection volumes and clinical outcomes in routine clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.